Cannabidiol modulation of hippocampal glutamate in early psychosis.

ABSTRACT:

Background

Emerging evidence supports the antipsychotic effect of cannabidiol, a non-intoxicating component of cannabis, in people with psychosis. Preclinical findings suggest that this antipsychotic effect may be related to cannabidiol modulating glutamatergic signalling in the brain.

Aim

The purpose of this study was to investigate the effects of cannabidiol on the neurochemical mechanisms underlying psychosis.

Methods

We investigated the effects of a single oral dose of cannabidiol (600 mg) in patients with psychosis, using a double-blind, randomised, placebo-controlled, repeated-measures, within-subject cross-over design. After drug administration, 13 patients were scanned using proton magnetic resonance spectroscopy to measure left hippocampal glutamate levels. S

SUBMITTER: O'Neill A 

PROVIDER: S-EPMC8278563 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature